3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
7
Terminated
1
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Lymphoma, Large B-Cell, Diffuse
3
Hodgkin Disease
3
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Uveal Melanoma
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pediatric Brain Tumor
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lymphoma, T-Cell
1
Lymphoma, Follicular
1
Lymphoma
1
Glioblastoma
1
Burkitt Lymphoma
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Cyclophosphamide
21
venetoclax
18
pembrolizumab
16
Dexamethasone
16
fludarabine
14
Cytarabine
13
Gemcitabine
9
pomalidomide
8
Rituximab
8
Carboplatin
8
Azacitidine
8
glofitamab
7
fludarabine phosphate
7
Lenalidomide
7
Immunotherapy, Adoptive
7
selinexor
6
Paclitaxel
6
Injections
6
Granulocyte Colony-Stimulating Factor
6
Cisplatin
6
daratumumab
5
Temozolomide
5
Oxaliplatin
5
Bevacizumab
5
zanubrutinib
4
ruxolitinib
4
Surgical Procedures, Operative
4
Nivolumab
4
Drug Therapy
4
Decitabine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Recurrence
×
Carmustine
×
Clear all
NCT04150042
2026-01-29
SHARON
General Oncology, Inc.
Phase 1
Recruiting
24 enrolled